hyperCORE International Strengthens Executive Team with New Vice President and Treasurer Appointments

hyperCORE International has announced significant updates to its executive leadership team with the appointment of Jeffrey Smyth as Vice President and Olivia McIver as Treasurer. These strategic additions strengthen the organization's governance structure and ensure continued alignment with hyperCORE's mission of driving efficiency and excellence across its collaborative network of clinical trial sites throughout North America.

Smyth brings extensive experience from his role as President and Executive Director of partner site network TrueBlue Clinical Research, while McIver joins from her position as Director of Clinical Operations at partner site network Applied Research Center. The complementary expertise these executives bring will support hyperCORE's ongoing growth initiatives and play a crucial role in overseeing financial stewardship while supporting long-term sustainability for the organization.

"hyperCORE's strength lies in its ability to unify best-in-class research sites through shared operational excellence," said Nicholas Focil, President of hyperCORE. "As we continue to grow, having a dedicated and strategic Vice President and integrated board Treasurer is essential to guide our leadership framework and maintain our strategic mobility across our industry."

The executive appointments come as hyperCORE continues to expand its network of partner site organizations, which include AGA Clinical Trials; Alcanza Clinical Research; Apex Trials; Applied Research Center; Atlas Clinical Research; CaRe Clinics; Epic Medical Research; FOMAT Medical Research; TrueBlue Clinical Research; and QCR Network. Each independently operated network participates in harmonized operational frameworks that streamline study delivery at scale across the clinical research landscape.

Alongside these new appointments, Nicholas Focil, CEO of FOMAT Medical Research, will continue serving as President, and Mark Scullion, CEO of Atlas Clinical Research, will maintain his role as Secretary. This continuity in leadership provides trusted guidance for hyperCORE's next phase of growth and development.

hyperCORE International represents a partner site network of leading clinical research organizations with impressive scale and experience. The network boasts over 80 active trial sites across five countries and two continents, with partners having jointly completed more than 7,500 studies involving over 150,000 randomized participants. The organization's model allows each partner member to operate independently while integrating harmonized operational frameworks to optimize efficiency, standardization, and excellence across all research activities.

The executive leadership enhancements underscore hyperCORE's commitment to advancing clinical research through safe, ethical, and timely studies while maintaining efficient enrollment and superior retention rates. The organization's approach is empowered by its members' consistent recognition through top-tier awards for performance, quality, and innovation in the clinical research field.